Table 5 Stem cell origin advantages, disadvantages and use in clinical and preclinical studies
From: Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research
Stem cell origin | Advantages | Disadvantages | Clinical studies | Preclinical studies | ||
|---|---|---|---|---|---|---|
Autologous | • Immunoincompatibility • No ethical conflict • No infection transmission risk | • Lower stem cell concentration and limited healing potential • Cell harvesting procedural risk | 32 | (89%) | 4 | (7%) |
Allogeneic | • Healthy stem cell source • No cell harvesting risk for DFU patient • Donor banking creation | • Relative immunoincompatibility • Need for disease screening • Ethical conflict | 4 | (11%) | 29 | (54%) |
Xenotransplantation | • No ethical conflict • Healthy stem cell source • No cell harvesting risk for DFU patient • Donor baking creation | • High immunoincompatibility • Need for disease screening | 0 | (0%) | 22 | (41%) |